Respiri Beheer

Beheer criteriumcontroles 1/4

De CEO Respiri is Marjan Mikel, benoemd in Dec2019, heeft een ambtstermijn van 4.92 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 758.38K, bestaande uit 56.5% salaris en 43.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.35% van de aandelen van het bedrijf, ter waarde A$ 364.69K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.4 jaar en 1.8 jaar.

Belangrijke informatie

Marjan Mikel

Algemeen directeur

AU$758.4k

Totale compensatie

Percentage CEO-salaris	56.5%
Dienstverband CEO	4.9yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	3.4yrs
Gemiddelde ambtstermijn bestuur	1.8yrs

Recente managementupdates

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08

Recent updates

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08

Analyse CEO-vergoeding

Hoe is Marjan Mikel's beloning veranderd ten opzichte van Respiri's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$758k	AU$428k	-AU$7m
Mar 31 2024	n/a	n/a	-AU$7m
Dec 31 2023	n/a	n/a	-AU$6m
Sep 30 2023	n/a	n/a	-AU$6m
Jun 30 2023	AU$570k	AU$428k	-AU$6m
Mar 31 2023	n/a	n/a	-AU$6m
Dec 31 2022	n/a	n/a	-AU$6m
Sep 30 2022	n/a	n/a	-AU$6m
Jun 30 2022	AU$607k	AU$428k	-AU$7m
Mar 31 2022	n/a	n/a	-AU$7m
Dec 31 2021	n/a	n/a	-AU$8m
Sep 30 2021	n/a	n/a	-AU$9m
Jun 30 2021	AU$2m	AU$428k	-AU$11m
Mar 31 2021	n/a	n/a	-AU$12m
Dec 31 2020	n/a	n/a	-AU$12m
Sep 30 2020	n/a	n/a	-AU$10m
Jun 30 2020	AU$2m	AU$187k	-AU$7m

Compensatie versus markt: De totale vergoeding ($USD 494.35K ) Marjan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 298.50K ).

Compensatie versus inkomsten: De vergoeding van Marjan is gestegen terwijl het bedrijf verliesgevend is.

CEO

Marjan Mikel

4.9yrs

Tenure

AU$758,383

Compensatie

Mr. Marjan Mikel, M.Com, BSc (Hons), Dip Ed, MAICD), serves as Chief Executive Officer and Managing Director at Respiri Limited since December 2, 2019 and serves as its Executive Director since November 25...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Nicholas Smedley	Executive Chairman	5.1yrs	AU$487.75k	1.26% A$ 1.3m
Marjan Mikel	CEO, MD & Executive Director	4.9yrs	AU$758.38k	0.35% A$ 373.8k
Peter Hildebrandt	Chief Operations Officer	4yrs	AU$276.55k	geen gegevens
George Vlachodimitropoulos	Chief Technology Officer	3.3yrs	AU$284.75k	geen gegevens
Samaneh Shirazi	Chief Research Officer	5.8yrs	AU$208.01k	geen gegevens
Theo Antonopoulos	Chief Commercial Officer	3.4yrs	AU$302.66k	geen gegevens
William Sigsbee	Head of US Operations & Chief Commercial Officer for the US market	1.6yrs	geen gegevens	geen gegevens
Justin Mouchacca	Joint Company Secretary	less than a year	geen gegevens	geen gegevens
Nova Taylor	Joint Company Secretary	less than a year	geen gegevens	geen gegevens
Noam Gavriely	Medical & Scientific Advisor	no data	AU$310.61k	geen gegevens
Simon Godfrey	Medical & Scientific Advisor	no data	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

Ervaren management: Het managementteam van RSH wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Nicholas Smedley	Executive Chairman	5.1yrs	AU$487.75k	1.26% A$ 1.3m
Marjan Mikel	CEO, MD & Executive Director	5yrs	AU$758.38k	0.35% A$ 373.8k
Gerard Criner	Member of Medical Advisory Board	1.8yrs	geen gegevens	geen gegevens
William Krimsky	Chair of Medical Advisory Board	1.8yrs	geen gegevens	geen gegevens
Bruce Thompson	Member of Medical & Scientific Advisory Board	no data	AU$1.47k	geen gegevens
Stephen Selinger	Member of Medical Advisory Board	1.8yrs	geen gegevens	geen gegevens
Jonathan Hovda	Member of Medical Advisory Board	1.8yrs	geen gegevens	geen gegevens
Tom Takubo	Non-Executive Director	less than a year	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van RSH wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.

Respiri Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Respiri Limited, Annual General Meeting, Nov 20, 2024

Respiri Limited Announces Executive Changes

Less than half of directors are independent

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Respiri Limited, Annual General Meeting, Nov 15, 2023

Respiri Limited Appoints Brian Leedman as Non-Executive Director

Recent updates

Respiri Limited, Annual General Meeting, Nov 20, 2024

Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.007 loss in FY 2023)

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

New major risk - Shareholder dilution

New major risk - Share price stability

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.6 million.

Respiri Limited Announces Executive Changes

New major risk - Share price stability

Respiri Limited has completed a Follow-on Equity Offering in the amount of AUD 1.3876 million.

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.

Less than half of directors are independent

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Respiri Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.009 loss in FY 2022)

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

New minor risk - Share price stability

Respiri Limited Appoints Brian Leedman as Non-Executive Director

First half 2023 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in 1H 2022)

Respiri Limited Announces Arkansas Heart Hospital Commences Patients on Wheezo RPM

Respiri Limited Announces Minnesota Lung Center Wheezo Rpm Pilot Program Patient Selection Has Been Finalised and Patient Onboarding Has Successfully Commence

No independent directors

Respiri Announces First Patients Enrolled into Wheezo® Remote Patient Monitoring Programs, Further Validating USA Business Model

Respiri Limited, Annual General Meeting, Nov 15, 2022

Full year 2022 earnings released

We're Keeping An Eye On Respiri's (ASX:RSH) Cash Burn Rate

Respiri Limited Announces Executive Changes

Respiri Limited Announces New £2 Million NIHR-Funded UK Paediatric Asthma Clinical Trial with wheezo

Respiri Limited Appoints Brad Snow as A Non-Executive Director

Respiri Limited Appoints Brad Snow as A Non-Executive Director

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Respiri Limited Announces Resignation of Director of Dr. Thomas Duthy

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Full year 2021 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in FY 2020)

Respiri Limited Announces Wheezo Registered and Approved for Sale in the UK Market

We Think Respiri (ASX:RSH) Can Afford To Drive Business Growth

Insider recently bought AU$95k worth of stock

Respiri (ASX:RSH) Is In A Good Position To Deliver On Growth Plans

Respiri Limited Announces New Partnership with Pharmacy 4 Less Banner Group

Respiri Limited Holds Media Events to Mark the Launch of Wheezo

Respiri Limited, Annual General Meeting, Dec 16, 2020

Respiri Limited Files Additional Patent Application

Respiri Limited Announces A Partnership with Entech Electronics for the Global Supply of the Ground Breaking Wheezo

Respiri Limited to Report Fiscal Year 2020 Results on Aug 25, 2020

Respiri Limited announced that it expects to receive AUD 0.09 million in funding

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur